secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aurinia Pharmaceuticals Inc. (AUPH)
CIK:        0001600620
Form:       8-K
Filed at:   2025-07-31T23:59:59+00:00
Accession:  0001600620-25-000090
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aurinia Q2 revenue up 22% to $70M; net income $21.5M; raises FY2025 guidance
----------------------------------------------------------------------------

- Total revenue $70.0M (+22% YoY); net product sales $66.6M (+21%); net income $21.5M vs $0.7M in Q2 2024.
- H1 2025 revenue $132.5M (+23%); net income $44.9M vs loss of $10.0M; operating cash flow $45.5M.
- FY2025 total revenue guidance raised to $260-270M (from $250-260M); net product sales $250-260M.
- Board approved $150M increase to share repurchase plan; $138.4M spent on 18.3M shares since Feb 2024.
- Positive Phase 1 data for dual BAFF/APRIL inhibitor aritinercept; plans to start Phase 2 in 2H 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1600620/000160062025000090/0001600620-25-000090-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1600620/000160062025000090/auph-20250731.htm
  HTML page:      https://secwatch.observer/filing/0001600620-25-000090

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer